Cell Therapy News/Articles, page-6984

Hopefully, I'm wrong about the Type A, but if I'm not it is just more time that we are wasting. What puzzles me about the FDA ruling is that MSB would have had a meeting with the FDA when they were designing the trial. Did MSB not understand what the FDA said at that meeting? Something does not add up.

"Unless the FDA are willing to link an accelerated approval (very limited with a heap of restrictions) to an emergency use approval (EUA) for Rem-L once there is adequate data for COVID ARDS, as the biology is similar. Which would be great."

As much as I'd like to think otherwise, I'm not sure the FDA would consider any data from the ARDS trial for the GVHD indication. Let's not forget that should MSB gain approval for C19 ARDS, they are likely to need further trial data for ARDS caused by flu or other ailments.

Also, thanks heaps for the background and info on Herceptin as I was unaware of it. I have a very close family member who has late stage breast cancer and is trying a bunch of stuff at the moment. I'll call her tonight to see if she's aware of it.

All is not lost for us Mesoblast shareholders, far from it. Now that most of the traders have abandoned ship we may start to become a little more civil on HC again